Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
201.93
-0.55 (-0.27%)
At close: Dec 5, 2025, 4:00 PM EST
201.98
+0.05 (0.02%)
After-hours: Dec 5, 2025, 7:59 PM EST
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.99B in the quarter ending September 28, 2025, with 6.77% growth. This brings the company's revenue in the last twelve months to $92.15B, up 5.08% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$92.15B
Revenue Growth
+5.08%
P/S Ratio
5.28
Revenue / Employee
$667,263
Employees
138,100
Market Cap
486.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
JNJ News
- 9 hours ago - Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC - PRNewsWire
- 2 days ago - Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 days ago - American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades - Seeking Alpha
- 4 days ago - 16 Quality Stocks to Own for a Volatile Market - Barrons
- 4 days ago - Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG) - GlobeNewsWire
- 5 days ago - 3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio - The Motley Fool
- 5 days ago - 2 Top Dividend Stocks to Buy and Hold - The Motley Fool
- 6 days ago - Best Dividend Aristocrats For December 2025 - Seeking Alpha